Press Releases April 28, 2026 06:45 AM

Burning Rock Publishes 2025 Annual Report on Form 20-F

Burning Rock Biotech files 2025 Annual Report on Form 20-F with SEC

By Caleb Monroe BNR
Burning Rock Publishes 2025 Annual Report on Form 20-F
BNR

Burning Rock Biotech Limited, a precision oncology company specializing in next generation sequencing, announced the filing of its Annual Report on Form 20-F for the fiscal year ending December 31, 2025. The report, which includes audited consolidated financial statements, is available through the SEC and company website. The company focuses on NGS-based therapy selection for late-stage cancer patients and cancer early detection, advancing clinical validation efforts.

Key Points

  • Burning Rock Biotech filed its 2025 Annual Report on Form 20-F with the U.S. SEC, demonstrating regulatory compliance and transparency.
  • The company specializes in next generation sequencing (NGS) technology applied to precision oncology, including therapy selection for late-stage cancer patients and early cancer detection.
  • Cancer early detection has progressed beyond proof-of-concept into clinical validation stage, indicating potential growth in diagnostic capabilities.

GUANGZHOU, China, April 28, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing technology in the field of precision oncology, announces that on April 28, 2026 it filed its Annual Report on Form 20-F for the year ended December 31, 2025 (the “Form 20-F”) with the U.S. Securities and Exchange Commission (“SEC”). The Form 20-F is available for viewing on the SEC website at www.sec.gov and also on the Company’s website at http://ir.brbiotech.com. The Company will provide a hard copy of the Form 20-F containing the audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. Requests should be directed to Burning Rock Biotech Limited, No.5 Xingdao Ring Road North, International Bio Island, Guangzhou, or via email at [email protected].

About Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.

For more information about Burning Rock, please visit: http://ir.brbiotech.com

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Contact: [email protected]


Risks

  • Forward-looking statements in the report highlight risks related to market and operating conditions that could cause actual results to differ materially from expectations.
  • Risks involve uncertainties inherent in the development and commercial adoption of advanced NGS technologies in oncology diagnostics.
  • The company faces regulatory, clinical validation, and market acceptance challenges which may impact future performance.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026